Neuroprotection: IV complex vs intranasal peptide

Cerebrolysin vs Semax

Comparing Cerebrolysin and Semax across evidence, dosing, mechanisms, and research areas.

Compound A

vs

Compound B

Cerebrolysin—

Category

cognitive

cognitive

Molecular weight

—

813.93 g/mol

Half-life

—

~30 minutes (intranasal)

Admin routes

—

intranasalsubcutaneous

Research areas

—

Cognitive enhancementNeuroprotectionStroke recoveryADHDAlzheimer's diseaseSpinal cord injury

Typical dosing

—

200–600 mcg · 1-2x daily · 2-4 weeks on, 2 weeks off

FDA status

not-FDA-approved

Not FDA-approved. Approved in Russia since 2011 for stroke, cognitive disorders, and peptic ulcers

WADA status

—

Not listed

PubMed studies

—

204

Full profile →Full profile →

More Comparisons

bpc-157 vs tb-500 cjc-1295 vs ipamorelin semaglutide vs tirzepatide ghk-cu vs ghk ghrp-2 vs ghrp-6 igf-1-lr3 vs igf-1-des semax vs selank epithalon vs ghk-cu bpc-157 vs ghk-cu pt-141 vs kisspeptin semaglutide vs aod-9604 tirzepatide vs mk-677 bpc-157 vs cerebrolysin tesamorelin vs cjc-1295 mk-677 vs ipamorelin thymosin-alpha-1 vs ll-37 mots-c vs nad-plus epithalon vs nad-plus semaglutide vs retatrutide